Galapagos NV (Galapagos NV) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Galapagos NV Days Payable?

Galapagos NV's average Accounts Payable for the three months ended in Dec. 2023 was $138.1 Mil. Galapagos NV's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.0 Mil.

The historical rank and industry rank for Galapagos NV's Days Payable or its related term are showing as below:

GLPG' s Days Payable Range Over the Past 10 Years
Min: 0 Med: 0 Max: 3645.16
Current: 3645.16

During the past 13 years, Galapagos NV's highest Days Payable was 3645.16. The lowest was 0.00. And the median was 0.00.

GLPG's Days Payable is ranked better than
91.89% of 715 companies
in the Biotechnology industry
Industry Median: 148.78 vs GLPG: 3645.16

Galapagos NV's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00). stayed the same

Galapagos NV Days Payable Historical Data

The historical data trend for Galapagos NV's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Days Payable Chart

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

Galapagos NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial															-	3,676.90	3,048.69	2,034.73	-

Competitive Comparison of Galapagos NV's Days Payable

For the Biotechnology subindustry, Galapagos NV's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Galapagos NV's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galapagos NV's Days Payable distribution charts can be found below:

* The bar in red indicates where Galapagos NV's Days Payable falls into.

Galapagos NV Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Galapagos NV's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (141.206	+	146.841)	/	2 )	/	0	*	365
=	144.0235					/	0	*	365
=	N/A

Galapagos NV's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (129.273	+	146.841)	/	2 )	/	0	*	365 / 4
=	138.057					/	0	*	365 / 4
=	N/A

Galapagos NV Days Payable Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV (Galapagos NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (NAS:GLPG) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

GLPG:Netherlands GLPG:Mexico 0JXZ:UK GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.